New site-agnostic therapies highlight the importance of genetic testing.

Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.

The findings could help identify patients who might benefit from combination therapy with a checkpoint blocker and another inhibitor.

The investigational machine has an 85% accuracy rate.

Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.

Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.

NKTR-214 plus Opdivo has been granted an FDA breakthrough therapy designation for advanced melanoma.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

Could new cancer drugs restore immune responses against HIV?

Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.